Prognostic Model Developed for Immunotx of Urothelial Cancer
Model, based on six factors, predicts overall survival for patients treated with atezolizumab
Officially it ’s a ‘unique holiday hotel for cancer patients and those with life-threatening illnesses’, according to the sign outside the Twenties green-shuttered building in Bournemouth.
Sarah Brookes, 41, a mother of two from Bradford, West Yorkshire, would like commercial sunbeds to be banned outright.
Publication date: August 2018Source: Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, Volume 1870, Issue 1Author(s): Chi Van Dang
Publication date: August 2018Source: Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, Volume 1870, Issue 1Author(s):
The steep increase in thyroid cancer diagnosis has not been mirrored by increasing mortality rates and is likely due to widespread overdiagnosis of small neoplasms.
The presence of HER3 expression and a high HER2/CEP17 ratio distinguish a group of invasive HER2-positive ductal breast cancer patients who have a worse prognosis.
Publication date: 13 August 2018Source: Cancer Cell, Volume 34, Issue 2Author(s): Manisha Rao, Scott PowersIn this issue of Cancer Cell, Menghi et al. show that tandem duplications (TDs) are a common genetic feature of gynecological and triple-negative breast cancers. They also provide evidence that these TDs generate genetic alterations driving these cancers, which, if substantiated, will fundamentally change our understanding of their oncogenesis.
Publication date: 13 August 2018Source: Cancer Cell, Volume 34, Issue 2Author(s): Carolyn Hurst, Jonathan Rosenberg, Margaret KnowlesBladder cancers, the majority of which are urothelial carcinoma, are the most common urinary tract cancers. There are two major disease types, muscle-invasive and non-muscle-invasive, with distinct pathogenesis pathways, molecular features, and clinical outcomes. Recent genomic and transcriptomic data have significantly improved tumor sub-classification and prognostication for both patient groups and are informing improved approaches to treatment of muscle-invasive disease. To view this SnapS...
Publication date: 13 August 2018Source: Cancer Cell, Volume 34, Issue 2Author(s): Gururaj Shivange, Karol Urbanek, Piotr Przanowski, Justin S.A. Perry, James Jones, Robert Haggart, Christina Kostka, Tejal Patki, Edward Stelow, Yuliya Petrova, Danielle Llaneza, Marty Mayo, Kodi S. Ravichandran, Charles N. Landen, Sanchita Bhatnagar, Jogender Tushir-SinghSummaryTherapeutic antibodies targeting ovarian cancer (OvCa)-enriched receptors have largely been disappointing due to limited tumor-specific antibody-dependent cellular cytotoxicity. Here we report a symbiotic approach that is highly selective and superior compared with in...
Publication date: 13 August 2018Source: Cancer Cell, Volume 34, Issue 2Author(s): Ramona Schulz-Heddergott, Nadine Stark, Shelley J. Edmunds, Jinyu Li, Lena-Christin Conradi, Hanibal Bohnenberger, Fatih Ceteci, Florian R. Greten, Matthias Dobbelstein, Ute M. MollSummaryOver half of colorectal cancers (CRCs) harbor TP53 missense mutations (mutp53). We show that the most common mutp53 allele R248Q (p53Q) exerts gain of function (GOF) and creates tumor dependence in mouse CRC models. mutp53 protein binds Stat3 and enhances activating Stat3 phosphorylation by displacing the phosphatase SHP2. Ablation of the p53Q allele suppres...